Transcatheter Valve Therapies event to take place from June 2-5

Meeting will feature the latest advances and techniques for the treatment of valvular heart disease

WHAT:
Press registration is now open for Transcatheter Valve Therapies: An Advanced Scientific and Clinical Workshop (with LAA Occlusion) at http://www.tvtconference.com/conference/press-registration.html. TVT is a unique educational event, offering an in-depth review of the diagnostic and therapeutic options for the treatment of valvular heart disease.

The meeting will feature the following topics:

  • Aortic Access, Anatomy, and Devices
  • Mitral Anatomy
  • New Aortic Valves
  • Live Cases

WHY:
Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, however, there have been important advances in concepts, tools, techniques, and patient selection for treatment of valvular heart disease using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.

WHEN:
June 2 - 5, 2012

WHERE:
Westin Seattle
Seattle, WA

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tirzepatide improves heart health and function in obese HFpEF patients